• linkedin
  • Increase Font
  • Sharebar

    What’s going to be hot in 2018?


    Help for hyperhidrosis

    Two dermatologists say that what they’re excited about for 2018 is the potential FDA approval for glycopyrronium tosylate (Dermira), a topical drug for the treatment of hyperhidrosis.

    Dr. Green“In 2018, I look forward to the hopeful approval and then launch of Dermira’s glycopyrronium tosylate for axillary hyperhidrosis. I think this will be a game-changer for people who suffer from excess under arm sweating, as it is an easy to use daily towelette,” says Lawrence J. Green, M.D., associate clinical professor of dermatology, George Washington University School of Medicine.

    Dermira is a once-daily topically applied anticholinergic agent, which has completed Phase 3 trials for the treatment of primary axillary hyperhidrosis. The therapy is designed to inhibit the interaction between acetylcholine and the cholinergic receptors responsible for sweat gland activation, according to company information.Dr. Glaser

    Phase 2 and 3 studies have shown good improvement in patients, with minimal side effects that were usually mild, according to Dee Anna Glaser, M.D., professor and interim chairman of dermatology at Saint Louis University School of Medicine.

    “This is a topical. It’s not an injection, and it’s not a procedure,” says Dr. Glaser, who is president of the International hyperhidrosis Society. “I think we’re going to see a whole new aspect of treatment that may allow more patients with hyperhidrosis to come in and get treatment.”

    Conflicts of interest: Dr. Green, none. Dr. Glaser, has research grants with Dermira, Allergan, Sienna. She serves on the advisory boards for Dermira, Allergan, Galderma, Merz and Brickell.

    NEXT: Injectable innovations

    Lisette Hilton
    Lisette Hilton, president of Words Come Alive, has written about health care, the science and business of medicine, fitness and wellness ...


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow